

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Encinitas, California–(September 25, 2024) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) (“Kiora” or the “Company”), will participate in the following investor conferences. The presentations will be accessible live and on-demand for 90 days from our IR homepage (ir.kiorapharma.com).

- **Lytham Partners Fall 2024 Investor Conference.**

Monday, October 1, 2024 at 10:15 am EDT

Presenter: Melissa Tosca, Chief Financial Officer

[Click here to register and view](#)

To arrange a meeting with management, please email 1x1@lythampartners.com

- **Maxim Virtual Healthcare Conference | Ophthalmology Panel**

Tuesday, October 15, 2024 at 11:00 am EDT

Presenter: Brian M. Strem, Ph.D., Chief Executive Officer

[Click here to sign up \(account creation required\), register and view](#)

- **LD Micro Conference**

Tuesday, October 29 at 4:00 pm EDT

Presenter: Melissa Tosca, Chief Financial Officer

[Click here to register and view](#)

About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

In addition to news releases and SEC filings, we expect to post information on our website (www.kiorapharma.com) and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Contacts:

Investors

investors@kiorapharma.com



To view the source version of this press release, please visit
<https://www.newsfilecorp.com/release/224520>